Skip to search formSkip to main contentSkip to account menu

Pegfilgrastim Biosimilar LA-EP2006

Known as: LA-EP2006 
A biosimilar of pegfilgrastim, a long-acting pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim, with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
LA-EP2006: A Pegfilgrastim Biosimilar
LA-EP2006 (Ziextenzo®) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor… 
2018
2018
Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
Background: Granulocyte colony-stimulating factors such as filgrastim and its long-acting version pegfilgrastim are widely used… 
2017
2017
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
Abstract Background Following the functional and physicochemical characterization of a proposed biosimilar, comparative clinical… 
2017
2017
Abstract P2-11-05: Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer: Pooled analysis of two randomized…
Background: Biosimilars are highly similar to a biological reference product with no clinically meaningful differences in terms… 
2016
2016
Abstract P1-10-01: A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer…
Background: An abbreviated pathway for biological products shown to be biosimilar to the reference product exists in Europe and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)